Tue, December 5, 2017
Mon, December 4, 2017
Fri, December 1, 2017
Thu, November 30, 2017
Wed, November 29, 2017
Tue, November 28, 2017
Mon, November 27, 2017

Debjit Chattopadhyay Initiated (SRPT) at Strong Buy and Held Target at $75 on, Dec 1st, 2017

Debjit Chattopadhyay of HC Wainwright & Co., Initiated "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $75 on, Dec 1st, 2017.

Debjit has made no other calls on SRPT in the last 4 months.



There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 1 agrees with Debjit's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Gena Wang of "Barclays" Maintained at Hold with Increased Target to $49 on, Thursday, October 26th, 2017


These are the ratings of the 2 analyists that currently disagree with Debjit


  • Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Monday, October 2nd, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $81 on, Thursday, September 7th, 2017